Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus

Key Takeaways Kodiak posted a Q2 loss of $1.03 per share, missing estimates and widening from last year.Higher R&D costs reflect increased clinical activity across Kodiak's late-stage pipeline.Key tarcocimab and KSI-501 study results are due in 2026, with KSI-101 data expected by early 2027.Kodiak Sciences (KOD) incurred a loss of $1.03 per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.01. The company had incurred a loss of 86 cents per share in the year-ago qu ...